



Claims

1. A compound of Formula (1):



or a salt thereof, wherein;


- 5 A is selected from the group consisting of:




X is an optionally substituted phenyl ring, an optionally substituted pyridyl ring or an optionally substituted imidazopyridine ring system;

- 10 R^1 and R^2 are independently H or a C_{1-3} alkyl group which is optionally substituted with one or more fluorine atoms; or R^1 and R^2 are joined to form a 3-6 membered carbocyclic ring which is optionally substituted with one or more fluorine atoms;
- R^3 is H, C_{1-3} alkyl or F;
- R^4 is H or C_{1-3} alkyl;
- 15 R^8 is C_{1-3} alkyl or a C_{3-6} cycloalkyl ring;
- and either R^{10} and R^{11} are both methyl or R^{10} and R^{11} are joined to form a cyclobutyl ring.

2. The compound according to claim 1, which is a compound of Formula (1a) or (1b):




(1a);




(1b);

or a salt thereof.

3. The compound according to claim 1 or claim 2, wherein X is an optionally substituted phenyl ring or an optionally substituted pyridyl ring.
4. The compound according to claim 1, which is a compound of Formula (2) or (2i):



(2);



(2i);

or a salt thereof, wherein;

Q, W and T are CH or N;


Z and Y are C or N;

where either one or none of Q, W, T, Y and Z is N, R⁵ is absent if Y is N and R⁶ is absent if Z is N;


R⁵ and R⁶ are independently selected from H, halo, CN, OH, SF₅, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, OR⁷ and SO₂R⁷, wherein the alkyl, cycloalkyl and alkoxy groups are optionally substituted with one or more fluorine atoms and any one atom of the alkyl or cycloalkyl group may be optionally replaced by a heteroatom selected from O, S and N; or R⁵ and R⁶ are joined to form a 5 or 6-membered carbocyclic or heterocyclic ring which is optionally substituted with one or more fluorine atoms;

and R⁷ is a C₁₋₆ alkyl group which is optionally substituted with one or more fluorine atoms or a C₃₋₆ cycloalkyl group which is optionally substituted with one or more fluorine atoms.

5. The compound according to claim 4, which is a compound of Formula (3) or (3i):




(3);




(3i);

or a salt thereof.

6. The compound according to any one of claims 1 to 5, wherein R¹ and R² are both methyl, R¹ and R² are both H, R¹ and R² are joined to form a cyclopropyl ring or R¹ is methyl and R² is H.
7. The compound according to claim 6, wherein R¹ is methyl and R² is H.
8. The compound according to claim 4, which is a compound of Formula (4) or (4i):




(4);




(4i);

or a salt thereof.

9. The compound according to claim 4, which is a compound of Formula (5) or (5i):



(5);




(5i);


or a salt thereof.

10. The compound according to any one of claims 4 to 9, wherein W, Q and T are CH
5 and Z and Y are C.

11. The compound according to claim 4, which is a compound of Formula (6) or (6i):



(6);



(6i);

or a salt thereof.

10

12. The compound according to any one of claims 1 to 11, wherein A is CO₂H,
CONHSO₂Me or a tetrazole ring.

13. The compound according to claim 12, wherein A is CO₂H.


15
















14. The compound according to any one of claims 1 to 13, wherein R³ is H or methyl.
















15. The compound according to claim 14, wherein R³ is H.
















- 20 16. The compound according to any one of claims 1 to 15, wherein R⁴ is H or methyl.
















17. The compound according to claim 16, wherein R^4 is H.
18. The compound according to any one of claims 4 to 17, wherein R^5 and R^6 are independently selected from H, Cl, F, CN, OH, SO_2Me , SO_2Et , SO_2 -cyclopropyl, SF_5 ,
 5 CF_3 , CF_2H , $OMe OCF_3$, OCF_2H , CH_2OH , CH_2OMe , cyclopropyl and oxetanyl.
19. The compound according to any one of claims 4 to 18, wherein R^5 is H.
20. The compound according to claim 19, wherein R^6 is CF_3 or F.
- 10 21. The compound according to any one of claims 4 to 17, wherein R^5 and R^6 are joined to form a fused imidazole ring or a fused dioxolane ring which is optionally substituted with one or two fluorine atoms.
- 15 22. The compound according to claim 1 which is selected from the group consisting of:














































101



or a salt thereof.

23. The compound according to any one of claims 1 to 22 having EP4 receptor antagonist activity.
24. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 23 and a pharmaceutically acceptable excipient.
25. The compound or composition according to any one of claims 1 to 24 for use in medicine.
26. The compound or composition according to any one of claims 1 to 24 for use in the treatment of Abdominal aortic aneurysm (AAA), Ankylosing spondylitis (AS), Alzheimer's disease, Atherosclerosis, Cancer including epithelial cancers (GBD neoplasm categories of colon and rectum, lip and oral cavity, nasopharynx, other pharynx, gallbladder and biliary tract, pancreatic, non-melanoma skin, ovarian, testicular, kidney, bladder, thyroid, mesothelioma, esophageal, stomach, liver, larynx, tracheal, bronchus and lung, breast, cervical, uterine, prostate), Diabetic nephropathy, Endometriosis, Inflammatory bowel disease, Migraine, Multiple sclerosis (MS), Osteoarthritis (OA) or Rheumatoid arthritis.